177

EXPRESS MAIL LABEL NO. EL754020489US
DATE OF DEPOSIT: April 6, 2001
PATENT
Attorney's Matter No. 4239-55414

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Tosato et al.

Application No.: To be assigned

Filed: Herewith

For: VASOSTATIN AS MARROW

PROTECTANT

Examiner: To be assigned

Date: April 6, 2001

Art Unit: To be assigned

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on April 6, 2001 as Express Mail Label No. EL754020489US in an envelope addressed to: BOX PATENT APPLICATION, COMMISSIONER FOR PATENTS, WASHINGTON.D.C. 202 1.

William

William D. Noonan, M.D. Attorney for Applicant

STATEMENT IN COMPLIANCE WITH 37 C.F.R. § 1.821(f)

BOX PATENT APPLICATION COMMISSIONER FOR PATENTS Washington, DC 20231

Sir:

In compliance with 37 C.F.R. § 1.821(f), the undersigned declares that the nucleotide and/or amino acid sequences presented in the paper copy of the "Sequence Listing" submitted herewith are the same as the sequences contained in the computer-readable form of said "Sequence Listing." No new matter has been added.

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL LEIGH & WHINSTON, LLP

By

William D. Noonan, M.D. Registration No. 30,878

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

SEQUENCE LISTING

·	
<110> Government of the United States of America	
<120> Vasostatin as Marrow Protectant	
<130> 4239-55414	
<160> 8	
<170> PatentIn version 3.0	
<210> 1 <211> 1251 <212> DNA <213> Calreticulin	
<400> 1	
atgctgctat ccgtgccgtt gctgctcggc ctcctcggcc tggccgtcgc cgagcctgcc	60
gtctacttca aggagcagtt tctggacgga gacgggtgga cttcccgctg gatcgaatcc	120
aaacacaagt cagattttgg caaattcgtt ctcagttccg gcaagttcta cggtgacgag	180
gagaaagata aaggtttgca gacaagccag gatgcacgct tttatgctct gtcggccagt	240
ttcgagcctt tcagcaacaa aggccagacg ctggtggtgc agttcacggt gaaacatgag	300
cagaacatcg actgtggggg cggctatgtg aagctgtttc ctaatagttt ggaccagaca	360
gacatgcacg gagactcaga atacaacatc atgtttggtc ccgacatctg tggccctggc	420
accaagaagg ttcatgtcat cttcaactac aagggcaaga acgtgctgat caacaaggac	480
atccgttgca aggatgatga gtttacacac ctgtacacac tgattgtgcg gccagacaac	540
acctatgagg tgaagattga caacagccag gtggagtccg gctccttgga agacgattgg	600
gacttcctgc cacccaagaa gataaaggat cctgatgctt caaaaccgga agactgggat	660
gagegggeea agategatga teccaeagae tecaageetg aggaetggga caageeegag	720
catatecetg accetgatge taagaageee gaggaetggg atgaagagat ggaeggagag	780
tgggaacccc cagtgattca gaaccctgag tacaagggtg agtggaagcc ccggcagatc	840
gacaacccag attacaaggg cacttggatc cacccagaaa ttgacaaccc cgagtattct	900
cccgatccca gtatctatgc ctatgataac tttggcgtgc tgggcctgga cctctggcag	960
gtcaagtctg gcaccatctt tgacaacttc ctcatcacca acgatgaggc atacgctgag	1020
gagtttggca acgagacgtg gggcgtaaca aaggcagcag agaaacaaat gaaggacaaa	1080
caggacgagg agcagaggct taaggaggag gaagaagaca agaaacgcaa agaggaggag	1140
gaggcagagg acaaggagga tgatgaggac aaagatgagg atgaggagga tgaggaggac	1200
aaggaggaag atgaggagga agatgtcccc ggccaggcca	1251

<210> 2

<211> 417

<212> PRT

<213> Calreticulin

<400> 2

Met Leu Ser Val Pro Leu Leu Gly Leu Leu Gly Leu Ala Val 1 5 10 15

Ala Glu Pro Ala Val Tyr Phe Lys Glu Gln Phe Leu Asp Gly Asp Gly 20 25 30

Trp Thr Ser Arg Trp Ile Glu Ser Lys His Lys Ser Asp Phe Gly Lys 35 40 45

Phe Val Leu Ser Ser Gly Lys Phe Tyr Gly Asp Glu Glu Lys Asp Lys 50 55 60

Gly Leu Gln Thr Ser Gln Asp Ala Arg Phe Tyr Ala Leu Ser Ala Ser 65 70 75 80

Phe Glu Pro Phe Ser Asn Lys Gly Gln Thr Leu Val Val Gln Phe Thr 85 90 95

Val Lys His Glu Gln Asn Ile Asp Cys Gly Gly Gly Tyr Val Lys Leu $100 \hspace{1.5cm} 105 \hspace{1.5cm} 110 \hspace{1.5cm}$

Phe Pro Asn Ser Leu Asp Gln Thr Asp Met His Gly Asp Ser Glu Tyr 115 120 125

Asn Ile Met Phe Gly Pro Asp Ile Cys Gly Pro Gly Thr Lys Lys Val 130 135 140

His Val Ile Phe Asn Tyr Lys Gly Lys Asn Val Leu Ile Asn Lys Asp 145 150 155 160

Ile Arg Cys Lys Asp Asp Glu Phe Thr His Leu Tyr Thr Leu Ile Val 165 170 175

Arg Pro Asp Asn Thr Tyr Glu Val Lys Ile Asp Asn Ser Gln Val Glu
180 185 190

Ser Gly Ser Leu Glu Asp Asp Trp Asp Phe Leu Pro Pro Lys Lys Ile 195 200 205

Lys Asp Pro Asp Ala Ser Lys Pro Glu Asp Trp Asp Glu Arg Ala Lys 210 215 220

Ile Asp Asp Pro Thr Asp Ser Lys Pro Glu Asp Trp Asp Lys Pro Glu225230235240

His Ile Pro Asp Pro Asp Ala Lys Lys Pro Glu Asp Trp Asp Glu Glu 245 250 255

Met Asp Gly Glu Trp Glu Pro Pro Val Ile Gln Asn Pro Glu Tyr Lys 260 265 270

Gly Glu Trp Lys Pro Arg Gln Ile Asp Asn Pro Asp Tyr Lys Gly Thr
Page 2

275 280 285

Trp Ile His Pro Glu Ile Asp Asn Pro Glu Tyr Ser Pro Asp Pro Ser 290 295 300

Ile Tyr Ala Tyr Asp Asn Phe Gly Val Leu Gly Leu Asp Leu Trp Gln 305 310 315

Val Lys Ser Gly Thr Ile Phe Asp Asn Phe Leu Ile Thr Asn Asp Glu 325 330 335

Ala Tyr Ala Glu Glu Phe Gly Asn Glu Thr Trp Gly Val Thr Lys Ala 340 345 350

Ala Glu Lys Gln Met Lys Asp Lys Gln Asp Glu Glu Gln Arg Leu Lys 355 360 365

Glu Glu Glu Glu Asp Lys Lys Arg Lys Glu Glu Glu Glu Ala Glu Asp 370 375 380

Lys Glu Asp Asp Glu Asp Lys Asp Glu Asp Glu Glu Asp Glu Glu Asp 395 400

Lys Glu Glu Asp Glu Glu Glu Asp Val Pro Gly Gln Ala Lys Asp Glu
405 410 415

Leu

<210> 3

<211> 180

<212> PRT

<213> Vasostatin

<400> 3

Glu Pro Ala Val Tyr Phe Lys Glu Gln Phe Leu Asp Gly Asp Gly Trp
1 10 15

Thr Ser Arg Trp Ile Glu Ser Lys His Lys Ser Asp Phe Gly Lys Phe 20 25 30

Val Leu Ser Ser Gly Lys Phe Tyr Gly Asp Glu Glu Lys Asp Lys Gly 35 40 45

Leu Gln Thr Ser Gln Asp Ala Arg Phe Tyr Ala Leu Ser Ala Ser Phe 50 55 60

Glu Pro Phe Ser Asn Lys Gly Gln Thr Leu Val Val Gln Phe Thr Val 65 70 75 80

Lys His Glu Gln Asn Ile Asp Cys Gly Gly Gly Tyr Val Lys Leu Phe 85 90 95

Pro Asn Ser Leu Asp Gln Thr Asp Met His Gly Asp Ser Glu Tyr Asn 100 105 110

Ile Met Phe Gly Pro Asp Ile Cys Gly Pro Gly Thr Lys Lys Val His 115 120 125

```
Val Ile Phe Asn Tyr Lys Gly Lys Asn Val Leu Ile Asn Lys Asp Ile
Arg Cys Lys Asp Asp Glu Phe Thr His Leu Tyr Thr Leu Ile Val Arg
 Pro Asp Asn Thr Tyr Glu Val Lys Ile Asp Asn Ser Gln Val Glu Ser
Gly Ser Leu Glu
<210> 4
<211> 61
<212> PRT
<213> Fragment 1
<400> 4
Thr Asp Met His Gly Asp Ser Glu Tyr Asn Ile Met Phe Gly Pro Asp
Ile Cys Gly Pro Gly Thr Lys Lys Val His Val Ile Phe Asn Tyr Lys
Gly Lys Asn Val Leu Ile Asn Lys Asp Ile Arg Cys Lys Asp Asp Glu
Phe Thr His Leu Tyr Thr Leu Ile Val Arg Pro Asp Asn
<210> 5
<211> 27
<212> PRT
<213> Fragment 2
<400> 5
Cys Gly Pro Gly Thr Lys Lys Val His Val Ile Phe Asn Tyr Lys Gly
Lys Asn Val Leu Ile Asn Lys Asp Ile Arg Cys
<210> 6
<211> 18
<212> PRT
<213> Fragment 3
<400> 6
Val Ile Phe Asn Tyr Lys Gly Lys Asn Val Leu Ile Asn Lys Asp Ile
Arg Cys
<210> 7
<211> 35
<212> PRT
```

Page 4

```
<213> Fragment 4
```

<400> 7

Arg Cys Lys Asp Asp Glu Phe Thr His Leu Tyr Thr Leu Ile Val Arg 20 25 30

Pro Asp Asn 35

<210> 8

<211> 61

<212> PRT

<213> Fragment 5

<400> 8

Cys Gly Pro Gly Thr Lys Lys Val His Val Ile Phe Asn Tyr Lys Gly
1 10 15

Lys Asn Val Leu Ile Asn Lys Asp Ile Arg Cys Lys Asp Asp Glu Phe 20 25 30

Thr His Leu Tyr Thr Leu Ile Val Arg Pro Asp Asn Thr Tyr Glu Val 35 40 45

Lys Ile Asp Asn Ser Gln Val Glu Ser Gly Ser Leu Glu 50 60